Divase, tablets 100 pcs

Combined drug:

Antibodies to brain-specific protein S-100 has antioxidant, antihypoxant, neuroprotective, anxiolytic effect. They modify the functional activity of protein S-100 that conjugates informational and metabolic processes in the brain. They have membranotropic effect, causing a decrease in the amplitude and suppression of action potential generation; they modulate synaptic plasticity in limbic structures of the brain, hippocampus, reticular formation; they contribute to enhance inhibitory effects of GABA in CNS.

Inhibit lipid peroxidation.

Have a normalizing effect on the integrative activity of the brain that shows a wide range of balanced psychopharmacological effects: antidepressant, anxiolytic, neuroprotective, antiasthenic, anti-amnestic.

Antibodies to endothelial NO synthase increase the activity of the enzyme of endothelial NO synthase, restore endothelial production of nitric oxide (NO), eliminate endothelial dysfunction, have endothelioprotective effect, influence NO-dependent vasodilation. The stimulating effect of Divase on reparative processes in the focus of ischemic brain damage has been experimentally shown.

The combined use of the components of the preparation is accompanied by the strengthening of the neuroprotective activity of antibodies to protein S-100, the strengthening of the vegetative-stabilizing effect, the normalization of the vegetative status, the synergistic effect of both components on neuronal plasticity and as a consequence, the increase of the brain resistance to toxic influences; Improves integrative activity and restores interhemispheric connections of the brain, helps eliminate cognitive disorders, stimulates reparative processes and accelerates restoration of CNS functions, increases mental performance, restores learning and memory processes, normalizes somatovenerative manifestations, increases cerebral blood flow.

Divase and its components do not have sedative and muscle relaxant effect, is not addictive and does not cause addiction.

Indications

Divaza is indicated for use in adults.
Complex treatment of asthenoneurotic and cognitive disorders caused by neurodegenerative and cerebrovascular (including ischemic) diseases of the brain.

Pharmacological effect

Pharmacotherapeutic group

Nootropic drug.

ATX codes

N06BX.

Pharmacological properties

Pharmacodynamics

Combination drug:

Antibodies to the brain-specific protein S-100 have antioxidant, antihypoxic, neuroprotective, and anxiolytic effects. They modify the functional activity of the S-100 protein, which combines information and metabolic processes in the brain. They have a membranotropic effect, causing a decrease in amplitude and suppression of the generation of action potentials; modulate synaptic plasticity in the limbic structures of the brain, hippocampus, and reticular formation; contribute to enhancing the inhibitory effects of GABA in the central nervous system. Shows sigma 1 receptor agonist properties in vitro.

Inhibits lipid peroxidation processes.

They have a normalizing effect on the integrative activity of the brain, which is manifested by a wide range of balanced psychopharmacological effects: antidepressant, anxiolytic, neuroprotective, antiasthenic, antiamnestic.

Antibodies to endothelial NO synthase increase the activity of the endothelial NO synthase enzyme, restore endothelial production of nitric oxide (NO), eliminate endothelial dysfunction, have an endothelial protective effect, and affect NO-dependent vasodilation.

The stimulating effect of Divaza on reparative processes in the focus of ischemic brain damage has been experimentally demonstrated.

The combined use of the components of the drug is accompanied by an increase in the neuroprotective activity of antibodies to the S-100 protein, an increase in the vegetative-stabilizing effect, normalization of the vegetative status, a synergistic effect of both components on neuronal plasticity, and, as a result, an increase in the brain’s resistance to toxic effects; improves integrative activity and restores interhemispheric connections of the brain, helps eliminate cognitive impairment, stimulates reparative processes and accelerates the restoration of central nervous system functions, increases mental performance, restores learning and memory processes, normalizes somatovegetative manifestations, increases cerebral blood flow.

Divaza, like its components, does not have a sedative or muscle relaxant effect, does not cause addiction or addiction.

Pharmacokinetics

The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, gas chromatography-mass spectrometry) does not allow assessing the content of the active substances of the drug Divaza in biological fluids, organs and tissues, which makes it technically impossible to study pharmacokinetics.

Special instructions

Can be used by patients with diabetes mellitus type I and II.

Impact on the ability to drive vehicles
During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions, since some patients may experience drowsiness.

Active ingredient

Antibodies

Composition

Active ingredients:

Antibodies to brain-specific protein S-100 affinity
peeled – 0.006 g*,

Affinity purified antibodies to endothelial NO synthase – 0.006 g*.

Excipients: lactose monohydrate, microcrystalline cellulose, magnesium stearate.

*applied to lactose in the form of a mixture of three active aqueous-alcoholic dilutions of the substance, diluted 10012, 10030, 100200 times, respectively.

Pregnancy

The safety of Divaza during pregnancy and breastfeeding has not been studied. If it is necessary to prescribe a drug, the benefit-risk ratio should be taken into account.

Contraindications

Increased individual sensitivity to the components of the drug. Divaza is not recommended for use in patients under 18 years of age due to insufficient data on efficacy and safety in this age group.
Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.

Side Effects

On the part of the immune system: reactions of increased individual sensitivity to the components of the drug are possible.
From the nervous system: drowsiness, headache.
The incidence of adverse reactions cannot be calculated from post-marketing surveillance.

Interaction

No cases of incompatibility with other drugs have been reported to date.

Overdose

In case of overdose, dyspepsia may occur due to the excipients included in the drug.

Storage conditions

In a place protected from light, at a temperature not exceeding 25 ° C.
Keep out of the reach of children.

Shelf life

3 years. Do not use after expiration date.

Manufacturer

Materia Medica Holding, Russia